Astronics is delivering exceptional aerospace growth and margin expansion, but ATRO’s $75.46 price already discounts much of the bullish recovery.
Overview
Astronics develops certified aerospace, defense, and mission-critical systems through Aerospace and Test Systems. The business has a differentiated position in cabin power and aircraft components, supported by FAA/EASA approvals, high switching costs, and the EmPower franchise. **Q2 2026 demonstrated substantial operating leverage:** sales rose 27.0% to $260.0 million, operating margin expanded to 15.6% from 2.3%, and adjusted EBITDA margin reached a multi-year high of 19.8%. The $780.6 million backlog, with 82% expected to convert within twelve months, and raised FY2026 revenue guidance of $1.02-$1.04 billion support continued momentum. The Lufthansa Technik UK appeal victory also reduces a significant legal overhang. However, the shares at $75.46 trade at more than 31x forward P/E and a 141.4% premium to the $31.25 DCF value. **The central investment tension is excellent execution versus limited valuation support.** Near-term catalysts include second-half production growth, BMA integration, retrofits, the U.S. Army radio test program, and possible legal cash recovery; the principal risk is that cyclical or execution setbacks expose the premium multiple.